Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials

Journal Article Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials Get access Akihiko Tanizawa, Akihiko Tanizawa Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer InstituteBethesda, Md. Present Address : A. Tanizawa, Department of Pediatrics, Fuki Medical College, 23 Matsuoka-cho Simoaizuki, Yoshida-gun, Fukui 910-11, Japan. Search for other works by this author on: Oxford Academic PubMed Google Scholar Akira Fujimori, Akira Fujimori Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer InstituteBethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Yuko Fujimori, Yuko Fujimori Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer InstituteBethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Yves Pommier Yves Pommier * Laboratory of Molecular Pharmacology, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer InstituteBethesda, Md. *Correspondence to : Y. Pommier, National Institutes of Health, Bldg. 37. Rm. 5C25, Bethesda, MD 20892. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 11, 1 June 1994, Pages 836–842, https://doi.org/10.1093/jnci/86.11.836 Published: 01 June 1994 Article history Received: 13 August 1993 Revision received: 18 February 1994 Accepted: 08 March 1994 Published: 01 June 1994